Hadean Ventures logo

Hadean Ventures

Europe, Oslo, Norway, Oslo

Description

Hadean is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.

Investor Profile

Hadean Ventures has made 25 investments, with 2 in the past 12 months and 44% as lead.

Stage Focus

  • Series A (36%)
  • Series Unknown (24%)
  • Series B (20%)
  • Series D (8%)
  • Series C (8%)
  • Post Ipo Equity (4%)

Country Focus

  • Sweden (32%)
  • Norway (16%)
  • Germany (12%)
  • Austria (8%)
  • United States (8%)
  • United Kingdom (4%)
  • Denmark (4%)
  • The Netherlands (4%)
  • Spain (4%)
  • Finland (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Biopharma
  • Artificial Intelligence (Ai)
  • Software
  • Assistive Technology
  • Personal Health
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Hadean Ventures frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Innovestor
Europe, Southern Finland, Finland, Helsinki
Co-Investments: 2
Bristol-Myers Squibb
North America, New York, United States, New York
Co-Investments: 2
Canica
Europe, Oslo, Norway, Oslo
Co-Investments: 2
Bonit Capital
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 3
Helicase Venture
North America, Massachusetts, United States, Boston
Co-Investments: 3
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 3
Scale Capital
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 2
Sunstone Life Science Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 3

What are some of recent deals done by Hadean Ventures?

Gesynta Pharma

Stockholm, Stockholms Lan, Sweden

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

BiopharmaHealth CarePharmaceutical
Series BJan 20, 2025
Amount Raised: $27,270,688
SciRhom

Martinsried, Bayern, Germany

SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.

BiotechnologyHealth Care
Series AJul 9, 2024
Amount Raised: $68,190,674
ARTHEx Biotech

Valencia, Comunidad Valenciana, Spain

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Biotechnology
Series BMay 3, 2023
Amount Raised: $46,487,689
Complement Therapeutics

London, England, United Kingdom

Complement Therapeutics operates as a preclinical stage company.

BiotechnologyMedical
Series AApr 17, 2023
Amount Raised: $78,657,148
Alex Therapeutics

Stockholm, Stockholms Lan, Sweden

AI digital CBT therapeutic platform - changing habits, changing health

Artificial Intelligence (AI)Assistive TechnologyHealth CareMedicalPersonal HealthSoftwareTherapeutics
Series UnknownMar 3, 2023
Amount Raised: $5,054,713
Alex Therapeutics

Stockholm, Stockholms Lan, Sweden

AI digital CBT therapeutic platform - changing habits, changing health

Artificial Intelligence (AI)Assistive TechnologyHealth CareMedicalPersonal HealthSoftwareTherapeutics
Series UnknownApr 6, 2022
Amount Raised: $3,814,194
TargED Biopharmaceuticals

Utrecht, Utrecht, The Netherlands

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AFeb 19, 2022
Amount Raised: $44,156,009
Ribbon Biolabs

Vienna, Wien, Austria

Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.

Biotechnology
Series AJan 31, 2022
Amount Raised: $20,212,909
Emergence Therapeutics

Duisburg, Nordrhein-Westfalen, Germany

Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.

BiotechnologyFitnessHealth CareWellness
Series ADec 7, 2021
Amount Raised: $98,075,135
Cardior Pharmaceuticals

Hanover, Niedersachsen, Germany

Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.

BiopharmaBiotechnologyPharmaceutical
Series BAug 25, 2021
Amount Raised: $75,344,022